As P529 is a novel Akt inhibitor (Xue et al, 2008) whose antitumour efficacy has been proven in vivo, we hypothesised that this drug could enhance the efficacy of RT in prostate cancer. The gene discussed is AKT1; the disease is prostate carcinoma.